Introduction {#s1}
============

IgLON5 antibody-associated encephalitis is a rare autoimmune-mediated disorder of the central nervous system often presenting with a tauopathy. Various clinical features have been described about anti-IgLON5 antibody-mediated encephalitis, such as sleep dysfunction (e.g. sleep-apnea, insomnia, and/or parasomnia), brainstem and/or cerebellar dysfunction (e.g. ataxia, abnormal ocular movements, dysphagia, or respiratory dysfunction), and neuropsychiatric symptoms like cognitive dysfunction ([@B1], [@B2]). The IgLON5 antigen is a cell-adhesion molecule whose functions are incompletely understood. We here describe for the first time the clinical case of a male patient presenting a subtle figural memory impairment in conjunction with numerous subjective cognitive complaints and additional neuropsychiatric symptoms associated with cerebrospinal fluid (CSF) anti-IgLON5 autoantibodies as an early manifestation of IgLON5 disease. This report's rationale is to highlight the subtle figural memory impairment together with other neuropsychiatric features as a relevant indicator for taking a sophisticated diagnostic approach encompassing the investigation of IgLON5 autoantibodies in CSF. We believe that the decision for initiating elaborated diagnostic methods in our case was essential, as the mortality of IgLON5 encephalitis can be high ([@B1], [@B3]).

Patient and Methods {#s2}
===================

We examined a 65-year-old Caucasian male patient who presented in our tertiary memory clinic. The patient is married and father of two children. He has an educational level of 13 years and works as an administration employee. Our diagnostic schedule comprised comprehensive neuropsychological assessment, electroencephalography (EEG), magnetic resonance imaging (MRI), peripheral blood (PB) and cerebrospinal fluid (CSF) analyses including specific antibodies and markers of neuronal degeneration, polysomnography (PSG) and neurography. Neuropsychological testing and follow-up after six months -- split into two sessions -- covered all major cognitive domains (language, attention, executive functions, visuoconstruction, and memory) and comprised the following instruments: Beck Depression Inventory (BDI-II), CDT (Clock Drawing Test), CERAD (consortium to establish a registry for Alzheimer´s disease)-plus, Mini-Mental Status Examination (MMSE), Regensburger word fluency test (RWT), Rey-Osterrieth-Complex-Figure test (ROCFT), and subtests from the Wechsler Adult Intelligence Scale IV (WAIS-IV) and Wechsler Memory-Scale IV (WMS-IV). We sought specific antibodies against paraneoplastic antigens *via* antibody blots \[Amphiphysin, CV2 (cronveinten 2), GAD65 (glutamic acid decarboxylase 65), HuD, Ma1/2, Ri, Ro, SOX1, TR, Zic4\] in CSF and PB. Furthermore, we did antibody testing of CSF and PB with recombinant-cell indirect immunofluorescence against neuronal antigens such as Aquaporin-, AMPAR1/2- (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor 1/2), CASPR2- (contactin-associated protein-like 2), DPPX- (dipeptidyl peptidase protein-like 6), GABAAR- (γ-aminobutyric acid A receptor), LGI1- (Leucine-rich glioma inactivated 1) and NMDAR- (N-methyl-D-aspartate receptor) antibodies. These antibodies were screened in the CSF laboratory in the Department of Neurology, University Medical Center Goettingen, IgLON5 antibodies were analyzed in the Euroimmun laboratory in Luebeck, Germany. We obtained informed consent from our patient and ethical approval. Our report concurs with the Declaration of Helsinki.

Results {#s3}
=======

Our patient presented at first with a striking subjective memory decline. He reported having experienced difficulty finding words, naming things and persons. Both his forgetfulness and high distractibility often resulted in misplacing everyday items such as keys, as his wife reported. He had great difficulty concentrating, and experienced sleep disturbances (sleeping less than 3--4 h and waking up early). Furthermore, he reported mild dysphagia, and problems with spatial orientation in a novel environment during the previous 9 months ([**Figure 1**](#f1){ref-type="fig"}). His wife also reported an increase in snoring over the last 9 months without its having interfered with his sleep. His daily living activities were unaffected. His medical history revealed no relevant comorbidities nor any relevant past or recurrent treatments. His mother suffers from parkinsonism. His physical examination exposed no pathological findings, but his neurologic examination revealed a known left-sided aniscoria. The patient found his cognitive deficits most afflicting; they had developed with a subacute onset, but no further deterioration. Cognitive screening results applying the MMSE and CDT were normal (MMSE=30/30, CDT=1), and the patient's self-report indicated a euthymic affective state (BDI-II=4) ([**Table 1**](#T1){ref-type="table"}).

![Time course of subjective and objective symptom evolution together with treatment. This schematic figure depicts the time course of symptoms from its first appearance, first presentation in hospital (onset) to their follow ups along with the performed diagnostic methods and corticosteroid treatment. CSF, cerebrospinal fluid analysis; EEG, electroencephalography; M, month; MRI, magnetic resonance imaging; NG, neurography; NPT, neuropsychological testing; PML, periodic limb movements; PSG, polysomnography; NP, neurography.](fpsyt-11-00576-g001){#f1}

###### 

Results of individual investigations at first visit and follow-up.

  Parameter                                     First visit   Follow-up
  --------------------------------------------- ------------- -----------
  **CSF analysis**                                            
  Cell count /ul (pathological: \>5 µl)         8             8
  Lymphocytes in %                              93            92
  Monocytes in %                                5             .
  Plasma cells in %                             2             2
  Albumin mg/L                                  518           615
  IgG mg/L                                      69.3          62.5
  IgA mg/L                                      10.7          9.6
  IgM mg/L                                      0.97          0.84
  QAlb %                                        11.5          15.4
  QIgG %                                        7.3           8.9
  QIgA %                                        4.3           5.2
  QIgM %                                        2.4           2.4
  Lactat mmol/L                                 2             2
  Oligoclonal IgG                               --            --
  NSE ng/ml (pathological: \>30 ng/ml)          19.3          .
  S100 µg/ml (pathological: \>2.7 µg/ml)        2             .
  Tau pg/ml (pathological: \>450 pg/ml)         409           .
  P-Tau 181 pg/ml (pathological: \> 61 pg/ml)   68            .
  Aß1-42 pg/ml (pathological: \>450 pg/ml)      715           .
  Aß1-40 pg/ml                                  9565          .
  Aß ratio pg/ml (pathological: \>0.5 pg/ml)    0.75          .
  **Serum**                                                   
  Oligoclonal IgG                               --            --
  CRP mg/l                                      42.5          1.1
  Leukocytes 10^3^ µl                           5.63          4.29
  **Neuropsychological testing\***                            
  MMSE                                          30            29
  CDT                                           01            01
  CERAD Boston Naming Test                      PR 31         PR 82
  CERAD semantic fluency                        PR 50         PR 66
  CERAD phonemic fluency                        PR 82         PR 62
  TMT part A                                    PR 76         PR 99
  WAIS-IV Digit Symbol Test                     PR 84         PR 95
  TMT division part B/A                         PR 84         PR 58
  RWT semantic fluency (alternating)            PR 30         PR 75
  RWT phonemic fluency (alternating)            PR 63         PR 54
  WAIS-IV Digit Span forward                    PR 05\*       PR 05\*
  WAIS-IV Digit Span backward                   PR 16         PR 16
  CERAD List Learning (trials 1-3)              PR 34         PR 34
  CERAD List Recall (savings)                   PR 46         PR 54
  CERAD List Recognition/discriminability       PR 21         PR 79
  WMS-IV Logical Memory I                       PR 50         PR 50
  WMS-IV Logical Memory II                      PR 16         PR 50
  CERAD Figure recall (savings)                 PR 01\*       PR 12\*
  WMS-IV Visual Reproduction I                  PR 25         PR 50
  WMS-IV Visual Reproduction II                 PR 50         PR 75
  CERAD Figure Copy                             PR 73         PR 18
  ROCFT Copy                                    PR\>16        PR\>16
  WAIS-IV Block Design                          PR 25         PR 75
  **Psychopathology**                                         
  BDI-II                                        04            05
  **Polysomnography**                                         
  Apnoe-Hypopnoe-Index                          .             9.7
  PLMI                                          .             64.6
  Basal 0~2~ desaturation %                     .             94
  Minimal 0~2~ desaturation %                   .             89.0
  0~2~ desaturation index %                     .             13

\*For better comparison, cognitive data is presented as percentiles (PR) unless otherwise indicated. Asterisk denote performance below the normal range (PR\<16). . = data not available. - = not present. Polysomnography data are derived from the second night.

AHI, apnoe-hyperpnoe index; Aß ratio, ß amyloid 1-42/1-40 ratio; Aß1-40, ß amyloid 1-40; Aß1-42, ß amyloid 1-42; BDI-II, Beck Depression Inventory; CSF, cerebrospinal fluid; IgA, immunoglobulin A; IgG, immunoglobulin G; IgM, immunoglobulin M; MMSE, Mini-Mental Status Examination; CDT, Clock Drawing Test; CERAD, Consortium to Establish a Registry for Alzheimer's Disease; TMT, Trail Making Test; RWT, ROCFT, Rey-Osterrieth-Complex-Figure test; WAIS-IV, Wechsler Adult Intelligence Scale IV; WMS-IV, Wechsler Memory-Scale IV, NSE, neuron specific enolase; O~2~ desaturation, oxygen desaturation; PLMI, periodic limb movement index; P-tau181, phosphorylated tau protein 181; QAlb, quotient albumin; QIgA, quotient immunoglobulin A; QIgG, quotient immunoglobulin G; QIgM, quotient immunoglobulin M; T-tau, total tau protein.

Most interestingly, cognitive impairment was detected in figural memory parameters in the CERAD-plus test battery, but not in the immediate and delayed recall in WMS-IV Visual Reproduction subtests, although the latter relies on more complex stimuli and entails a longer delayed recall interval. A slight impairment was also observed in his verbal memory span (WAIS-IV Digit Span forward), while all other cognitive functions appeared unaffected ([**Table 1**](#T1){ref-type="table"}). At neuropsychological follow-up six months later, we detected a similar pattern with stable, subtle impairments in figural memory and working memory ([**Figure 1**](#f1){ref-type="fig"}, [**Table 1**](#T1){ref-type="table"}). Modest improvements in other cognitive parameters must be interpreted cautiously and while considering practice effects.

For differential diagnosis, we performed lumbar puncture, analyzed CSF, and detected a pleocytosis of leukocytes (for specifications see [**Table 1**](#T1){ref-type="table"}). Specific antibodies (see methods) in PB and CSF were not detected. Furthermore, we identified in the CSF a blood-brain barrier disturbance and markers of neuroaxonal damage such as mildly elevated phosphorylated Tau-181 protein with 86 pg/ml (normal range ≤ 61 pg/ml). Peripheral inflammation was indicated by elevated C-reactive protein (CRP) with 42.5 mg/l (normal range \< 5 mg/l) and an elevated blood sedimentation rate (1h: 86/2h: 88 mm according to Westergren). MRI revealed frontal subcortical lesions on the right-side and a few unspecific periventricular white-matter lesions. EEG recordings showed neither epileptic potentials nor focal slowing ([**Figure 2**](#f2){ref-type="fig"}).

![Brain magnetic resonance imaging and polysomnography. Brain magnetic resonance imaging (Siemens Avanto 1.5 T). Axial T2w **(A, B)** and coronal FLAIR **(C, D)**. Hyperintense periventricular and juxtacortical white matter lesions. No specific MRI findings for IgLON5-associated encephalitis. **(E)** In the upper graph the hypnogram is shown as a function of time of the day (hours: minutes: seconds) with W representing wakefulness, R representing rapid eye movement (REM) sleep and N1-3 representing non-REM-sleep stages 1 to 3. In the lower graph oxygen saturation measured *via* pulse oximetry is depicted as a function of time of the day (hours: minutes: seconds) ranging from 50 to 100%.](fpsyt-11-00576-g002){#f2}

CSF diagnostics revealed a pleocytosis, a blood--brain barrier disturbance together with mild unspecific neurodegeneration, elevated phosphorylated tau-protein, and negative standard panel of specific autoantibodies (see *Methods*, [**Table 1**](#T1){ref-type="table"}). Our patient had reported sleeping dysfunction in addition to his figural and working memory impairment. Sleeping dysfunction is a prominent symptom of IgLON5 disease ([@B4]--[@B6]). His clinical syndrome, which comprised cognitive deficits together with sleeping abnormalities in conjunction with signs of CNS inflammation was our rationale to search for anti-IgLON5 antibodies (Euroimmun Laboratory, Luebeck, Germany) beyond the standard antibody panel. Anti-IgLON5 antibodies in serum (1:320) and CSF (1:3200) were detected *via* indirect immunofluorescence assay. Finally, we diagnosed an autoimmune encephalitis associated with anti-IgLON5 antibodies according to the Graus criteria ([@B7]) and started high-dosage therapy with methylprednisolone (1g/d i.v. over five days), to be continued over 6 months with 5 days of corticosteroids administered monthly as first therapy of choice in autoimmune encephalitis. Two weeks after having starting this well-tolerated corticosteroid treatment with no report of any adverse event, the patient complained at follow-up of dysphagia that he had noticed for several months but which he had ignored until then. In addition, he reported at follow-up (and after 3 cycles of corticosteroids) that he had been sleeping better (for 6 h uninterrupted), although he still suffers daytime sleepiness. His subjective memory impairments were less pronounced at follow-up, but he complained further of increased hypersalivation, his calves twitching, and of worse subjective dysphagia at follow-up. An endoscopic examination of his throat revealed no cause for his dysphagia. We decided to continue monthly intravenous administration of high-dose corticosteroids due to his improved cognitive and sleeping function. A follow-up neuropsychiatric examination 3 months after his initial presentation revealed ataxia of extremities ([**Figure 1**](#f1){ref-type="fig"}) that had disappeared by his final follow-up 7 months after initial presentation. In the meantime, he was diagnosed with axonal sensorimotor polyneuropathy *via* neurophysiologic measurements 3 months after his initial presentation ([**Figure 1**](#f1){ref-type="fig"}), but another investigator could not confirm that finding neurographically at his last follow-up. PSG given over three nights 6 months after his initial presentation ([**Figure 2**](#f2){ref-type="fig"}) revealed central (and mainly in supine position) obstructive sleep apnea and oxygen desaturation as low as 89% ([**Table 1**](#T1){ref-type="table"}, [**Figure 2E**](#f2){ref-type="fig"}). However, after being given an additional pillow to discourage back sleeping, his obstructive apnea lessened. We also observed increased period limb movements (PLM) in PSG. At his last follow-up 7 month after initial presentation, MRI showed known frontal subcortical lesions on the right side and periventricular white matter lesions ([**Figures 2A--D**](#f2){ref-type="fig"}) and a previously undescribed mild global atrophy. His last follow-up EEG still revealed no pathological signs. Subsequent CSF analysis showed a pleocytosis ([**Table 1**](#T1){ref-type="table"}) and a blood-brain barrier disturbance. Again, indirect immunofluorescence assay revealed anti-IgLON5 antibodies in serum and CSF at follow up.

Discussion {#s4}
==========

With our patient's cognitive testing results, the clinical IgLON5 syndrome's spectrum is expanded to include figural memory impairment. Very few patients with IgLON5 antibody-positive encephalitis and cognitive dysfunction have been reported in the literature so far ([@B1], [@B2], [@B8]--[@B11]). This could be due to both the lack of neuropsychological testing and IgLON5 disease's broad clinical spectrum---often presenting with predominant sleep dysfunction and motor impairment ([@B9]). So far, the cognitive spectrum of IgLON5 disease covers deficits in attention, information-processing speed, disinhibition and executive dysfunction, as well as impaired verbal memory performance ([@B1], [@B2], [@B8]--[@B11]), often progressing from mild cognitive impairment to dementia ([@B10], [@B11]). The pathophysiological mechanism of figural memory dysfunction in IgLON5 disease remains unclear. However, we hypothesize that IgLON5 autoantibodies result in phosphorylated Tau-deposits within the right hippocampus, as this structure is involved in figural memory function ([@B12]). A recent study demonstrated phosphorylated Tau-protein pathology in temporal regions including specific hippocampal subfields such as the cornu ammonis 1 (CA1) and the subiculum ([@B13]) concurring with a hypothetical mechanism for our patient's figural memory impairment.

To monitor his figural memory impairment, we will therefore continue to examine this patient's cognitive status. What is more, our patient's concomitant features like insomnia, dysphagia, concomitant tau pathology, and mild CSF pleocytosis correspond closely with IgLON5 disease ([@B1], [@B2]). Our diagnostic approach entailing repeated CSF analysis providing stable proof of IgLON5 antibodies in the CSF delivers solid evidence for probable autoimmunity. In addition, the repeated confirmation of CSF antibodies together with signs of a CNS inflammation impels us to diagnose a definitive IgLON5 autoimmune encephalitis, and eliminates the consideration of IgLON5 antibodies as an epiphenomenon. Two other main differential diagnosis were initially evaluated. First, we initially considered whether this patient might have prodromal Lewy-body dementia with mild cognitive impairment, as he presented with figural memory impairment. However, what argued against the LBD assumption was his lack of core symptoms such as parkinsonism, lack of rapid eye movement (REM)-sleep behavior disorder (RBD) or REM-sleep without atonia (RWA), and his failure to exhibit fluctuating cognition. The lack of RBD and RWA was later confirmed polysomnographically (PSG). Second, cerebrovascular disease was another potential candidate causing cognitive dysfunction, as his MRI had revealed periventricular white matter lesions that might imply cerebrovascular disease, but could also be attributable to the underlying autoimmune process. However, having identified anti-IgLON5 autoantibodies within the CSF finally confirmed the diagnosis of IgLON5-autoimmune encephalitis. Further evidence for an autoimmune-based mechanism in our IgLON5 syndrome is derived from the known association between IgLON5 antibodies and human leukocyte antigen (HLA) class II ([@B14]). In addition, the subcortical right frontal cortex lesions, periventricular white matter lesions and mildly generalized atrophy on brain MRI is another potential microstructural indication of an underlying autoimmune process *via* a disturbed blood-brain barrier and the infiltration of IgLON5 autoantibodies. However, no specific IgLON5 lesions have been detected in MRI ([**Figures 2A--D**](#f2){ref-type="fig"}). Furthermore, and although it is much less likely, a concomitant vascular pathology as differential diagnosis cannot be entirely ruled out as an additional cause for these structural brain abnormalities.

From already published data and the present case, it seems likely that IgLON5 antibody-associated autoimmune encephalitis is under-diagnosed and that affected patients are going untreated despite the symptoms' potential (at least partial) reversibility under therapy, as various studies have shown ([@B2], [@B9], [@B11], [@B15]). Although self-reported improved memory is a low-evidence parameter for the efficacy of corticosteroids, lessened axonal neuropathy, no longer detectable ataxia of extremities, and less pronounced sleeping dysfunction at follow-up seem to reveal additional evidence favoring the efficacy of corticosteroids in our case. Patients presenting with cognitive impairment and IgLON5 syndrome often seem to experience better outcomes ([@B15], [@B16])---an observation in line with our patient's good response to therapy so far. However, the proof of CSF IgLON5 autoantibodies and signs of CNS inflammation at follow-up support an ongoing disease state. This patient's follow-up status must therefore be carefully observed, and should his clinical condition turn progressively worse, we would consider a rationale for escalating his therapy, i.e., *via* plasmapheresis. Azathioprine and mycophenolate mofetil are also known to be effective in long-term treatment for IgLON5 encephalitis ([@B15]). Nevertheless, noteworthy is our case report's inherent limitation as a single case report that enables only a low evidence level.

Taken together, even in patients presenting with subtle cognitive impairments in conjunction with sleeping dysfunction, a more specific diagnostic approach including neuropsychological assessment and CSF analysis should be taken to detect IgLON5 positive-encephalitis as a relevant differential diagnoses. The good responsivity that this patient's cognitive impairment revealed is in line with the literature on IgLON5 syndrome ([@B15]) and concurs with our patient's encouraging prognosis.
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